scholarly journals Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins

2010 ◽  
pp. 45
Author(s):  
Yusuf Rajabally
Keyword(s):  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Intravenous Immunoglobulins ◽  
Demyelinating Polyneuropathy ◽  
Inflammatory Demyelinating Polyneuropathy

scholarly journals Intravenous Immunoglobulins (IVIG) in Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ): time to maximal recovery

2015 ◽  
Vol 42 (S1) ◽  
pp. S34-S34
Author(s):  
S Baker ◽  
A Opala
Keyword(s):  
Treatment Time ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Intravenous Immunoglobulins ◽  
Demyelinating Polyneuropathy ◽  
Secondary Outcome ◽  
Ivig Treatment ◽  
European Federation ◽  
Inflammatory Demyelinating Polyneuropathy ◽  
Changes Over Time ◽  
Over Time

Background: The response of Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) to Intravenous Immunoglobulins (IVIG) treatment is well established. However, determination whether patients who do not respond to 2 IVIG treatments or those whose condition stabilizes (ICE Trial) would benefit from additional treatments remains unclear. We aim to identify time period required to reach maximal strength gains from IVIG treatment (plateau). Furthermore, we will assess nerve conduction studies (NCS) changes over time with IVIG treatment. This will help in establishing a time course for treatment of CIDP with IVIG to maximize recovery. Methods: We performed a retrospective chart review of 27 patients with CIDP, with diagnosis confirmed by European Federation of Neurological Societies/Peripheral Nerve Society Guidelines (EFNS/PNS). Each patient’s strength response including: grip strength, knee extension, elbow flexion and dorsiflexion (using JAMAR Dynamometer) and NCS changes over time during IVIG treatment were analyzed. The primary outcome is duration of IVIG treatment, in months, required to reach a plateau in strength. Secondary outcome is NCS change including: Terminal Latencies, Conduction Velocities, Compound Sensory and Motor action potentials in nerves of upper and lower extremities over treatment time (emerging trends). Results: Pending (available by April 2015) Conclusion: Pending (available by April 2015)

scholarly journals P.031 Intravenous immunoglobulins (IVIG) therapy in chronic inflammatory demyelinating polyneuropathy (CIDP): time to maximal recovery

2019 ◽  
Vol 46 (s1) ◽  
pp. S22
Author(s):  
A Opala ◽  
S Baker
Keyword(s):  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Retrospective Chart Review ◽  
Ivig Therapy ◽  
Elbow Flexion ◽  
Intravenous Immunoglobulins ◽  
Knee Extension ◽  
Demyelinating Polyneuropathy ◽  
Ivig Treatment ◽  
Maximal Strength ◽  
Inflammatory Demyelinating Polyneuropathy

Background: The response of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to Intravenous Immunoglobulins (IVIG) treatment is well established . However, determination if patients not responding to 2 IVIG treatments or those whose condition stabilizes (ICE Trial) may benefit from additional doses remains unclear. We aim to identify time period required to reach maximal strength gains from IVIG treatment. Methods: Retrospective chart review of 14 patients with CIDP was performed. Change in Grip strength (GS), Knee extension (KE), Elbow Flexion (EF) and Dorsflexion(DF) was analyzed with a dynamometer during IVIG therapy. Averages for : percent change from baseline(Max%Δ),cumulative grams(g) of IVIG and time in weeks(w) required for maximal strength recovery was determined per function (+/−SEM).Anciliary therapy for all patients was recorded. Results: Strongest improvement was observed for DF(124+/−30%,p<0.001), followed by KE(113+/−19%,p<0.01),GS(100+/−21%,p<0.001) and EF(98+/−14%p<0.05).GS improved the fastest(19.1+/−3w) followed by DF(29.5+/−7w),KE(29.6+/−4w) and EF(31+/−6w). Cumulative IVIG dose to reach Max%Δ was highest for EF(869+/−201g) and lowest for GS(573+/−78g). Conclusions: Our study has demonstrated effectiveness of multiple treatments with IVIG to reach significant improvement in strength. Different muscle groups manifested different time-dependency ,reflecting variable amounts of IVIG required. Improvement was identified to be present on a ongoing basis ,with therapy lasting between 19.1-31 weeks,requiring between 869-573g of IVIG.

Electrophysiological and neuromuscular stability of persons with chronic inflammatory demyelinating polyneuropathy

2017 ◽  
Vol 56 (3) ◽  
pp. 413-420 ◽  
Author(s):  
Kevin J. Gilmore ◽  
Matti D. Allen ◽  
Timothy J. Doherty ◽  
Kurt Kimpinski ◽  
Charles L. Rice
Keyword(s):  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Demyelinating Polyneuropathy ◽  
Inflammatory Demyelinating Polyneuropathy
Sign in / Sign up

Export Citation Format

Share Document